{"DataElement":{"publicId":"5577914","version":"1","preferredName":"Person Asymptomatic Central Nervous System Disease Prior Treatment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to asymptomatic central nervous system disease and previous therapies.","longName":"ASYM_TX_CNSDZ_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"5577913","version":"1","preferredName":"Person Asymptomatic Central Nervous System Disease or Disorder Prior Therapeutic Procedure Clinical Trial Eligibility Criteria","preferredDefinition":"A human being._Having no signs or symptoms of disease._The part of the nervous system that consists of the brain, spinal cord, and meninges._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Earlier in time or order._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2236731v1.0:5577911v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5577911","version":"1","preferredName":"Asymptomatic Central Nervous System Disease or Disorder Prior Therapeutic Procedure Clinical Trial Eligibility Criteria","preferredDefinition":"Having no signs or symptoms of disease.:The part of the nervous system that consists of the brain, spinal cord, and meninges.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Earlier in time or order.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"5577911v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Asymptomatic","conceptCode":"C3833","definition":"Without clinical signs or indications that raise the possibility of a particular disorder or dysfunction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Central Nervous System","conceptCode":"C12438","definition":"The part of the nervous system that consists of the brain, spinal cord, and meninges.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4172E805-F0C1-7D6B-E053-F662850A1E08","latestVersionIndicator":"Yes","beginDate":"2016-11-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-16","modifiedBy":"ONEDATA","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4172E805-F0D2-7D6B-E053-F662850A1E08","latestVersionIndicator":"Yes","beginDate":"2016-11-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-16","modifiedBy":"TAYLORT","dateModified":"2016-11-30","changeDescription":"11/30/16 approved/released. 11/16/16 tt. 10005","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876426","version":"1","longName":"Physical & Concomitant Requirements","context":"Theradex"},{"publicId":"3876422","version":"1","longName":"Disease Status & Genetics","context":"Theradex"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Theradex - 1","type":"Alternate Question Text","description":"If patient has asymptomatic treated CNS metastases, have all of the criteria listed above been met as well as the  following: radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study, no stereotactic radiation or whole-brain radiation within 28 days prior to Cycle 1, Day 1; and screening CNS radiographic study greater than or equal to 4 weeks from completion of radiotherapy and greater than or equal to 2 weeks from discontinuation of corticosteroids?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"If patient has asymptomatic treated CNS metastases, have all of the criteria listed above been met as well as the  following: radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study, no stereotactic radiation or whole-brain radiation within 28 days prior to Cycle 1, Day 1; and screening CNS radiographic study greater than or equal to 4 weeks from completion of radiotherapy and greater than or equal to 2 weeks from discontinuation of corticosteroids?","url":null,"context":"Theradex"},{"name":"If patient has asymptomatic t","type":"Preferred Question Text","description":"If patient has asymptomatic treated CNS metastases are all of the criteria listed above met as well as the following:  Radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study; No stereotactic radiation or whole-brain radiation within 28 days prior to Cycle 1, Day 1;  Screening CNS radiographic study greater than or equal to 4 weeks from completion of radiotherapy and greater than or equal to 2 weeks from discontinuation of corticosteroids.","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"If patient has central nervous system (CNS) metastases is it inactive, defined as: no signs of cerebral edema after successful definitive treatment of brain metastases (surgical resection, whole brain irradiation, stereotactic radiation therapy, or a combination of these) with stable or improved radiographic appearance on magnetic resonance imaging (MRI) scan at least 1 month after completion of treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"If patient has asymptomatic treated CNS metastases are all of the criteria listed above met as well as the following:  Radiographic demonstration of clinical stability upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study; no stereotactic radiation or whole-brain radiation within 28 days prior to randomization; and screening CNS radiographic study greater than or equal to 4 weeks from completion of radiotherapy and greater than or equal to 2 weeks from discontinuation of corticosteroids?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"If patient has asymptomatic treated CNS metastases are all of the criteria listed above met as well as the following:  Radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and radiographic screening for the current study; No stereotactic radiation or whole-brain radiation within 28 days prior to Cycle 1, Day 1;  Screening CNS radiographic study greater than or equal to 4 weeks from completion of radiotherapy and greater than or equal to 2 weeks from discontinuation of corticosteroids","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"If patient has central nervous system (CNS) metastases is it inactive, defined as: symptoms of brain metastases after successful definitive treatment of brain metastases (surgical resection, whole brain irradiation, stereotactic radiation therapy, or a combination of these) with stable or improved radiographic appearance on magnetic resonance imaging (MRI) scan at least 1 month after completion of treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"If patient has central nervous system (CNS) metastases is it inactive, defined as: No symptoms of brain metastases after successful definitive treatment of brain metastases (surgical resection, whole brain irradiation, stereotactic radiation therapy, or a combination of these) with stable or improved radiographic appearance on magnetic resonance imaging (MRI) scan at least 1 month after completion of treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"If patient has asymptomatic treated CNS metastases, are all of the criteria listed above met as well as the following: Radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study; No stereotactic radiation or whole-brain radiation within 28 days prior to Cycle 1, Day 1; Screening CNS radiographic study greater than or equal to 4 weeks from completion of radiotherapy and greater than or equal to 2 weeks from discontinuation of corticosteroids.","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"If patient has asymptomatic treated CNS metastases, have all the following criteria listed above been met as well as the following: radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and radiographic screening for the current study, no stereotactic radiation or whole-brain radiation within 28 days prior to Cycle 1, Day 1, and screening CNS radiographic study greater than or equal to 4 weeks from completion of radiotherapy and greater than or equal to 2 weeks from discontinuation of corticosteroids?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"41729FAF-8242-42A0-E053-F662850AF34D","latestVersionIndicator":"Yes","beginDate":"2016-11-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-16","modifiedBy":"SOKKERL","dateModified":"2022-03-09","changeDescription":"2020-7-24 AQT added. AK 12/5/16 tt, added CSI and corrected typo in def. 11/30/16 approved/released. 11/16/16 tt, 10005","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}